East, Philip http://orcid.org/0000-0001-5801-5713
Kelly, Gavin P. http://orcid.org/0000-0001-7219-560X
Biswas, Dhruva http://orcid.org/0000-0001-9141-5188
Marani, Michela
Hancock, David C.
Creasy, Todd
Sachsenmeier, Kris
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Downward, Julian http://orcid.org/0000-0002-2331-4729
de Carné Trécesson, Sophie http://orcid.org/0000-0002-9341-2586
,
Article History
Received: 26 May 2021
Accepted: 12 September 2022
First Online: 26 September 2022
Competing interests
: J.D. has acted as a consultant for AstraZeneca, Bayer, Novartis, TheRas, Vividion, Jubilant and has received research funding from AstraZeneca, Bristol Myers Squibb and Revolution Medicines. SCT has acted as a consultant for Revolution Medicines. C.S. is a co-founder of Achilles Therapeutics, receives grant support from Pfizer, AstraZeneca, BMS, Roche–Ventana and Boehringer Ingelheim, has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche–Ventana, GRAIL, Medicxi and the Sarah Cannon Research Institute, is a shareholder of ApoGen Biotechnologies, Epic Bioscience and GRAIL. K.S. and T.C. were employees of AstraZeneca at the time the study was carried out. None of the other authors of this manuscript have a financial or non-financial interest related to this work.